

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, <u>Chayama K</u> , Alrefai WA, Uprichard SL.	Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.	Nat Med.	18	281-285	2012
Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K, <u>Chayama K</u> .	IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.	J gastroenterol.	47	834-844	2012
Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y, <u>Chayama K</u> .	Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.	J Infect Dis.	205	204-210	2012
Nagaoki Y, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H, <u>Chayama K</u> .	Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis.	J gastroenterol.			2012
Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Kimura T, Kenjo M, Nagata Y, Ishikawa M, Kakizawa H, Awai K, <u>Chayama K</u> .	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava.	Hepatol Res.	42	442-453	2012
Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y, <u>Chayama K</u> .	Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.	J Viral Hepat.	19	e126-133	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuo J, Mizui M, Okita H, Katayama K, Aimitsu S, Sakata T, Obayashi M, Nakanishi T, <u>Chayama K</u> , Miyakawa Y, Yoshizawa H, Tanaka J, for the Hiroshima Hepatitis Study G.	Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18 years.	Hepatol Res.	42	637-647	2012
Kumada H, Toyota J, Okanoue T, <u>Chayama K</u> , Tsubouchi H, Hayashi N.	Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.	J Hepatol.	56	78-84	2012
Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Chayama K</u> , Miyakawa Y, Kumada H.	Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.	J gastroenterol.	47	596-605	2012
Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, <u>Chayama K</u> .	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.	J Gastroenterol Hepatol.	27	1467-1472	2012
Karino Y, Toyota J, Ikeda K, Suzuki F, <u>Chayama K</u> , Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H.	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.	J Hepatol.			2012
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, <u>Chayama K</u> , Ohdan H.	Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.	Ann Surg Oncol.	19	418-425	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hayes CN, Imamura M, Aikata H, <u>Chayama K</u> .	Genetics of IL28B and HCV – response to infection and treatment.	Gastroenterology &Hepatology	9	406-417	2012
Hayashi N, Okanoue T, Tsubouchi H, Toyota J, <u>Chayama K</u> , Kumada H.	Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.	Journal of Viral Hepatitis	19	134-142	2012
<u>Chayama K</u> , Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.	Dual Therapy With the Nonstructural Protein 5A Inhibitor, Daclatasvir, and the Nonstructural Protein 3 Protease Inhibitor, Asunaprevir, in Hepatitis C Virus Genotype 1b-Infected Null Responders.	Hepatology	55	742-748	2012
<u>Chayama K</u> , Hayes CN, Ohishi W, Kawakami Y.	Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.	J Gastroenterol	48	1-12	2013
<u>Chayama K</u> , Hayes CN, Imamura M.	Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication.	Hepatology Research	42	841-853	2012
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Chayama K</u> , Nakamura Y, Kumada H.	Amino Acid substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy.	Intervirology	55	231-241	2012
Yanagimoto S, Yotsuyanagi H, Kikuchi Y, Tsukada K, Kato M, Takamatsu J, Hige S, <u>Chayama K</u> , Moriya K, Koike K.	Chronic hepatitis B in patients coinfecting with human immunodeficiency virus in Japan: a retrospective multicenter analysis.	J Infect Chemother	18	883-890	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H, <u>Chayama K.</u>	Severe Necroinflammatory Reaction Caused by Natural Killer Cell-Mediated Fas/Fas Ligand Interaction and Dendritic Cells in Human Hepatocyte Chimeric Mouse.	Hepatology	56	555-566	2012
Ohishi W, <u>Chayama K.</u>	Treatment of chronic hepatitis B with nucleos(t)ide analogues.	Hepatology Research	42	219-225	2012
Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, <u>Chayama K.</u>	Recent trend of clinical features in patients with hepatocellular carcinoma.	Hepatology Res.	42	368-375	2012
Miki D, Ochi H, Hayes CN, Aikata H, <u>Chayama K.</u>	Hepatocellular carcinoma: towards personalized medicine.	Cancer Sci.	103	846-850	2012
Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsunami H, Nagaoka S, <u>Chayama K.</u> , Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.	Hepatology Res.	42	139-149	2012
Hayes CN, Akamatsu S, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, <u>Chayama K.</u>	Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle.	PLoS One.	7	e47490	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, <u>Chayama K</u> , Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H.	Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.	Nat Genet.	44	760-764	2012
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, <u>Chayama K</u> , Yatsuhashi H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFNalpha-2a inpatients with chronic hepatitis C: a nationwide multicenter cooperative study.	J gastroenterol.			2012
Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M, Takeyama Y, Irie M, Shakado S, Sohda T, <u>Sakisaka S</u> .	Limitation of Repeated Radiofrequency Ablation in Hepatocellular Carcinoma: Proposal of a 3 (times)-3 (years)-INDEX.	J Gastroenterol Hepatol	27(6)	1044-1050	2012
Hirano G, Sakurai K, Sohda T, Kunimoto H, Yotsumoto K, Fukunaga A, Iwashita H, Ueda S, Yokoyama K, Morihara D, Takeyama Y, Sakamoto M, Irie M, Iwata K, Shakado S, <u>Sakisaka S</u> .	Systemic Chemotherapy Using Carboplatin and 5-Fluorouracil for Extrahepatic Metastasis of Hepatocellular Carcinoma.	Hepatogastroenterology	59(2)		2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Shakado S, Sohda T, Watanabe H, <u>Sakisaka S.</u>	Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma.	Hepatology Research	42	658-667	2012
Tanaka T, Shakado S, Takata K, Inomata S, Ueda S, Morihara D, Yokoyama K, Nishizawa S, Sakamoto M, Anan A, Takeyama Y, Irie M, Iwata K, Sohda T, <u>Sakisaka S.</u>	Hepatitis C virus-infected patients with persistently normal alanine aminotransferase levels whose platelet count less than 150,000/ μ L and whose age over 55 years old should be recommended antiviral therapy.	Med. Bull. Fukuoka Univ	39(2)	103-112	2012
Hikita H, Kodama T, Shimizu S, Li W, Shigekawa M, Tanaka S, Hosui A, Miyagi T, Tatsumi T, Kanto T, Hiramatsu N, Morii E, Hayashi N, <u>Takehara T.</u>	Bak deficiency inhibits liver carcinogenesis: A causal link between apoptosis and carcinogenesis.	J Hepatol.	57(1)	92-100.	2012
Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, <u>Takehara T.</u>	Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.	J Gastroenterol.	47(3)	334-42	2012
Imakiire K, Uto H, Sato Y, Sasaki F, Mawatari S, <u>Ido A.</u> , Shimoda K, Hayashi K, Stuver SO, Ito Y, Okanoué T, Tsubouchi H	Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.	Mol Med Rep	6	259-264	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tsubouchi N, Uto H, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Oketani M, <u>Ido A</u> , Hayashi K, Kusumoto K, Shimoda K, Stuver SO, Tsubouchi H	Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study.	Hepatol Res. 2013 Feb 18.		doi: 10.1111/he pr.12075. [Epub ahead of print]	2013
Ozaki T, Yamazaki K, Iwasaki T, Okano T, Kurosaki Y, Nakamura K, Fujioka T, <u>Yotsuyanagi H</u>	α 2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C.	Clin Chem Lab Med.			2012
Takeji S, Hirooka M, Koizumi Y, Tokumoto Y, Abe M, Ikeda Y, Nadano S, <u>Hiasa Y</u> , Onji M.	Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma.	J Gastroenterol Hepatol.	E-pub		2012
Uesugi K, <u>Hiasa Y</u> , Tokumoto Y, Mashiba T, Koizumi Y, Hirooka M, Abe M, Matsuura B, Onji M.	Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma.	J Gastroenterol.	E-pub		2012
Miyake T, <u>Hiasa Y</u> , Hirooka M, Tokumoto Y, Watanabe T, Furukawa S, Ueda T, Yamamoto S, Kumagi T, Miyaoka H, Abe M, Matsuura B, Onji M.	High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus.	Lipids	47	1601-9	2012
Tada F, Abe M, Hirooka M, Ikeda Y, <u>Hiasa Y</u> , Lee Y, Jung NC, Lee WB, Lee HS, Bae YS, Onji M.	Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.	Int J Oncol	41	1601-9	2012
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, <u>Hiasa Y</u> , Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arie S, Nishio K, Kudo M.	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	E-pub		2012


発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akbar SM, Chen S, Al-Mahtab M, Abe M, <u>Hiasa Y</u> , Onji M.	Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.	Antiviral Res	96	59-64	2012
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, <u>Hiasa Y</u> , Chayama K, Yatsunami H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	E-pub		2012
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, <u>Hiasa Y</u> , Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y, Tokunaga K, Mizokami M.	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.	PLoS One	7	e39175	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, <u>Hiasa Y</u> , Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K.	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet	13	47	2012
Yamamoto Y, <u>Hiasa Y</u> , Murakami H, Ikeda Y, Yamanishi H, Abe M, Matsuura B, Onji M.	Rapid alternative absorption of dietary long-chain fatty acids with upregulation of intestinal glycosylated CD36 in liver cirrhosis.	Am J Clin Nutr	96	90-101	2012
Ochi H, Hirooka M, Koizumi Y, Miyake T, Tokumoto Y, Soga Y, Tada F, Abe M, <u>Hiasa Y</u> , Onji M.	Real-time tissue elastography forevaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases.	Hepatology	56	1271-8	2012
Tokumoto Y, <u>Hiasa Y</u> , Uesugi K, Watanabe T, Mashiba T, Abe M, Kumagi T, Ikeda Y, Matsuura B, Onji M.	Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.	J Infect Dis	205	1121-30	2012
Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K, <u>Hiasa Y</u> , Matsuura B, Onji M.	Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.	J Gastroenterol	47	696-703	2012
Kumagi T, Drenth JP, Guttman O, Ng V, Lilly L, Therapondos G, <u>Hiasa Y</u> , Michitaka K, Onji M, Watanabe Y, Sen S, Griffiths W, Roberts E, Heathcote J, Hirschfield GM.	Biliary atresia and survival into adulthood without transplantation:a collaborative multicentre clinic review.	Liver Int	32	510-8	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ogawa E, Furusyo N, Kajiwaru E, Takahashi K, <u>Nomura H</u> , Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study J.	J Hepatol	(in press)		
Miyagi Y, <u>Nomura H</u> , Yamashita N, Tanimoto H, Ito K, Masaki N, Mizokami M, Shibuya T.	Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.	J Infect Chemother	(in press)		
Ogawa E, Furusyo N, Kajiwaru E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.	An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.	J Infect Chemother	18	689-697	2012
Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, <u>Nomura H</u> , Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S.	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.	Hepatol Res.	42	958-965	2012
Ogawa E, Furusyo N, Kajiwaru E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.	An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS).	J Gastroenterol Hepatol.	27	1233-1240	2012
Kainuma M, Furusyo N, Azuma K, Kajiwaru E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Shimoda S, Hayashi J.	Pegylated interferon alpha-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.	Hepatol Res.	42	33-41	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Nomura H</u> , Miyagi Y, Tanimoto H, Yamashita N, Oohashi S, Nishiura S.	Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin	Hepatol Res.	42	241-247	2012
<u>Nomura H</u> , Miyagi Y, Tanimoto H, Yamashita N, Ito K, Masaki N, Mizokami M.	Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.	J Gastroenterol Hepatol.	27	1461-1466	2012
<u>Yoshioka K</u> , Hashimoto S	Can non-invasive assessment of liver fibrosis replace liver biopsy?	Hepatol Res	42(3)	233-40	2012
Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Nakano M, Urano F, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H.	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.	J Med Virol	84(3)	438-44	2012
Gotoh K, Inoue M, Masaki T, Chiba S, Shimasaki T, Ando H, Fujiwara K, Katsuragi I, Kakuma T, <u>Seike M</u> , Sakata T, Yoshimatsu H.	A novel anti-inflammatory role for spleen-derived interleukin-10 in obesity-induced hypothalamic inflammation.	J Neurochem.	120	753-64	2012
Gotoh K, Inoue M, Masaki T, Chiba S, Shimasaki T, Ando H, Fujiwara K, Katsuragi I, Kakuma T, <u>Seike M</u> , Sakata T, Yoshimatsu H.	A novel anti-inflammatory role for spleen-derived interleukin-10 in obesity-induced inflammation in white adipose tissue and liver.	Diabetes.	61(8)	1994-2003	2012
Honda K, <u>Seike M</u> , Maehara S, Tahara K, Anai H, Moriuchi A, Muro T.	Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis.	World J Gastroenterol.	18 (20)	2586-90.	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kawaguchi T, Komori A, <u>Seike M</u> , Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M.	Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.	J Gastroenterol.	47 (12)	1342-51.	2012
Gotoh K, Inoue M, Masaki T, Chiba S, Shiraishi K, Shimasaki T, Matsuoka K, Ando H, Fujiwara K, Fukunaga N, Aoki K, Nawata T, Katsuragi I, Kakuma T, <u>Seike M</u> , Yoshimatsu H.	Obesity-related chronic kidney disease is associated with spleen-derived IL-10.	Nephrol Dial Transplant.	0	1-15	2012
Abe K, Katsushima F, Kanno Y, Takahashi A, Yokokawa J, Ohira H, Arinaga T, Ide T, Nishimura J, Inoue M, <u>Seike M</u> , Imazeki F, Yokosuka O, Sata M.	Clinical features of cirrhosis in Japanese patients with type I autoimmune hepatitis.	Intern Med.	51 (24)	3323-8	2012
Gotoh K, Inoue M, Shiraishi K, Masaki T, Chiba S, Mitsutomi K, Shimasaki T, Ando H, Fujiwara K, Katsuragi I, Kakuma T, <u>Seike M</u> , Sakata T, Yoshimatsu H.	Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease.	PLoS One.	7(12)	e53154	2012
Ninomiya M, <u>Ueno Y</u> , Funayama R, Nagashima T, Nishida Y, Kondo Y, Inoue J, Kakazu E, Kimura O, Nakayama K, Shimosegawa T.	Use of illumina deep sequencing technology to differentiate hepatitis C virus variants.	J Clin Microbiol	50(3)	857-66	2012
Kondo Y, <u>Ueno Y</u> , Ninomiya M, Tamai K, Tanaka Y, Inoue J, Kakazu E, Kobayashi K, Kimura O, Miura M, Yamamoto T, Kobayashi T, Igarashi T, Shimosegawa T.	Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.	J Gastroenterol.	47 (12):	1323-35	2012
Inoue J, <u>Ueno Y</u> , Kawamura K, Yamamoto T, Mano Y, Miura M, Kobayashi T, Niitsuma H, Kondo Y, Kakazu E, Ninomiya M, Kimura O, Obara N, Kawagishi N, Kinouchi Y, Shimosegawa T.	Association between S21 substitution in the core protein of hepatitis B virus and fulminant hepatitis.	J Clinical Virol	55 (2):	147-52.	2012



201227002B(2/4)

平成22年度
研究成果の刊行物

厚生労働科学研究費補助金

肝炎等克服緊急対策研究事業（肝炎分野）

ウイルス性肝炎における最新の治療法の
標準化を目指す研究

平成22年度～平成24年度 総合研究報告書

研究代表者 熊田 博光

平成25（2013）年3月

Ⅲ. 平成22年度 研究成果の刊行に関する一覧表

Ⅲ. 研究成果の刊行に関する一覧表

書籍

太字のみ研究成果の刊行物として記載

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
芥田憲夫 熊田博光	肝疾患治療薬～B型・C型肝炎における抗ウイルス療法・抗炎症療法～	高久史麿	治療薬ハンドブック2010	じほう	東京都	2010	513-533
熊田博光	C型肝炎の診療ガイドライン	幕内雅敏 菅野健太郎 工藤正俊	今日の消化器疾患治療指針 第3版	Medic Media	東京都	2010	991-993
岡上 武	慢性肝炎の治療(B型)	幕内雅俊、 菅野健太郎、 工藤正俊。	今日の消化器疾患治療指針	医学書院	東京	2010	580-583
黒崎雅之、 泉並木	B型肝炎に対する抗ウイルス治療	林紀夫、 日比紀文、 上日紀夫	Annual Review 消化器	中外医学社	東京	2011	137-45
田中智大、 泉並木	肝臓癌	佐藤千史、 井上智子	人体の構造と機能からみた病態生理	金原出版	東京	2010	93-100
工藤正俊、 泉並木	序文	工藤正俊、 泉並木	ウイルス肝炎の治療戦略	診断と治療社	東京	2010	vi-vii
田中榮司、 宮川眞一、 角谷眞澄		田中榮司、 宮川眞一、 角谷眞澄	肝疾患クリニカルスタンダード	文光堂	東京	2010	
清家正隆	NASH	犀川哲展 吉松博信	糖尿病と心臓病	医学書院	東京	2010	34-41
清家正隆	脂肪肝	吉松博信	肥満症	日本医事新報社	東京	2010	69-74

雑 誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Miyakawa Y, <u>Kumada H</u>	Influence of ITPA Polymorphisms on Decrease of hemoglobin during treatment with pegylated interferon, ribavirin and telaprevir	Hepatology	53 (2)	416-421	2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u> .	Amino acid substitutions in HCV core region and genetic variation near the interleukin 28B gene effect viral dynamics during telaprevir with peginterferon and ribavirin	Intervirology	DOI: 10.1159/000323526	In press	2011
Tadokoro K, Suzuki F, Kobayashi M, Yamaguchi T, Nagano M, Egashira T, <u>Kumada H</u>	Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-invader assay.	J Virol Method	171	67-73	2011
Hayes CN, Kobayashi M, Akuta N, Suzuki F, <u>Kumada H</u> , Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut.	60	261-267	2011
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, <u>Kumada H</u> , Izumi N, Mizokami M, Kudo M.	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009.	Hepatol Res.	41	1-21	2011
Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, zumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, <u>Kumada H</u> .	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res.	in press	in press	2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u> .	Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin	Hepatology	52 (2)	421-429	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, <u>Kumada H.</u>	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, <u>Kumada H.</u>	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J cln virol	47 (1)	76-78	2010
Arase Y, Suzuki F, Suziki Y, Akuta N, Kobayashi M, Sezaki H, Hosaka T, Kawamura Y, Yatsuji H, Hirakawa M, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.	J Med Virol	82	390-395	2010
Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, <u>Kumada H.</u>	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.	Hepatol Res	40 (2)	125-134	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H.</u>	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	40 (2)	145-152	2010
<u>Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.</u>	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	1-7	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Kumada H.</u> , Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	8-13	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H.</u>	Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.	J Med Virol	82	575-582	2010
Watanabe S, Enomoto N, Koike K, Isumi N, Takikawa H, Hashimoto E, Moriyasu F, <u>Kumada H.</u> , Imawari M, PERFECT study group.	Prolonged treatment with pegylated interferon $\alpha 2b$ plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-144	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H.</u>	Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.	Intervirol	53	188-192	2010
Arase Y, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.	Int Med	49	957-963	2010
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, <u>Kumada H.</u>	Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	Hepatol Res	25	892-898	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H.</u>	HBcrAg is predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.	Liv Int	93 (3-4)	109-112	2010
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Suzuki Y, Arase Y, <u>Kumada H.</u>	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma.	Hepatol Res	40 (10)	1006-1014	2010
Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, <u>Kumada H.</u>	Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.	Hepatol Res	40 (12)	1168-1175	2010
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Suzuki Y, Arase Y, <u>Kumada H.</u>	Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.	Am J Med	123 (10)	951-956	2010
Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, <u>Kumada H.</u>	Clinical and virological effects of long-term (over 5 years) lamivudine therapy.	J Med Virol	82	684-691	2010
Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, <u>Kumada H.</u>	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis.	Dig Dis Sci	55	2070-2076	2010
Izumi N, Nishiguchi S, Hino K, Suzuki F, <u>Kumada H.</u> Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M	Management of hepatitis C; report of the consensus meeting at the 45 th annual meeting of the Japan Society of Hepatology (2009).	Hepatol Res	40	347-68	2010